163 related articles for article (PubMed ID: 31359391)
1. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.
Jurutka PW; Wagner CE
Methods Mol Biol; 2019; 2019():95-108. PubMed ID: 31359391
[TBL] [Abstract][Full Text] [Related]
2. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
Wagner CE; Jurutka PW
Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
[TBL] [Abstract][Full Text] [Related]
3. An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
Jurutka PW; di Martino O; Reshi S; Mallick S; Sausedo MA; Moen GA; Lee IJ; Ivan DJ; Krall TD; Peoples SJ; Perez A; Tromba L; Le A; Khadka I; Petros R; Savage BM; Salama E; Salama J; Ziller JW; Noh Y; Lee MY; Liu W; Welch JS; Marshall PA; Wagner CE
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555852
[TBL] [Abstract][Full Text] [Related]
4. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN).
Heck MC; Wagner CE; Shahani PH; MacNeill M; Grozic A; Darwaiz T; Shimabuku M; Deans DG; Robinson NM; Salama SH; Ziller JW; Ma N; van der Vaart A; Marshall PA; Jurutka PW
J Med Chem; 2016 Oct; 59(19):8924-8940. PubMed ID: 27592633
[TBL] [Abstract][Full Text] [Related]
5. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
Jurutka PW; di Martino O; Reshi S; Mallick S; Sabir ZL; Staniszewski LJP; Warda A; Maiorella EL; Minasian A; Davidson J; Ibrahim SJ; Raban S; Haddad D; Khamisi M; Suban SL; Dawson BJ; Candia R; Ziller JW; Lee MY; Liu C; Liu W; Marshall PA; Welch JS; Wagner CE
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830251
[TBL] [Abstract][Full Text] [Related]
6. Modeling, synthesis, and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene) and (E)-3-(3-(1,2,3,4-tetrahydro-1,1,4,4,6-pentamethylnaphthalen-7-yl)-4-hydroxyphenyl)acrylic acid (CD3254).
Jurutka PW; Kaneko I; Yang J; Bhogal JS; Swierski JC; Tabacaru CR; Montano LA; Huynh CC; Jama RA; Mahelona RD; Sarnowski JT; Marcus LM; Quezada A; Lemming B; Tedesco MA; Fischer AJ; Mohamed SA; Ziller JW; Ma N; Gray GM; van der Vaart A; Marshall PA; Wagner CE
J Med Chem; 2013 Nov; 56(21):8432-54. PubMed ID: 24180745
[TBL] [Abstract][Full Text] [Related]
7. Rexinoids modulate steroid and xenobiotic receptor activity by increasing its protein turnover in a calpain-dependent manner.
Pettersson F; Hanna N; Lagodich M; Dupéré-Richer D; Couture MC; Choi C; Miller WH
J Biol Chem; 2008 Aug; 283(32):21945-52. PubMed ID: 18544536
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
Gorgun G; Foss F
Blood; 2002 Aug; 100(4):1399-403. PubMed ID: 12149223
[TBL] [Abstract][Full Text] [Related]
9. Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas.
Warda A; Staniszewski LJP; Sabir Z; Livingston S; Sausedo M; Reshi S; Ron E; Applegate MT; Haddad D; Khamisi M; Marshall PA; Wagner CE; Jurutka PW
Cells; 2023 Nov; 12(21):. PubMed ID: 37947652
[TBL] [Abstract][Full Text] [Related]
10. Next-generation retinoid X receptor agonists increase ATRA signaling in organotypic epithelium cultures and have distinct effects on receptor dynamics.
Melo N; Belyaeva OV; Berger WK; Halasz L; Yu J; Pilli N; Yang Z; Klyuyeva AV; Elmets CA; Atigadda V; Muccio DD; Kane MA; Nagy L; Kedishvili NY; Renfrow MB
J Biol Chem; 2023 Jan; 299(1):102746. PubMed ID: 36436565
[TBL] [Abstract][Full Text] [Related]
11. Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention.
Zhang D; Leal AS; Carapellucci S; Shahani PH; Bhogal JS; Ibrahim S; Raban S; Jurutka PW; Marshall PA; Sporn MB; Wagner CE; Liby KT
Cancer Prev Res (Phila); 2019 Apr; 12(4):211-224. PubMed ID: 30760500
[TBL] [Abstract][Full Text] [Related]
12. Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
Wagner CE; Jurutka PW; Marshall PA; Groy TL; van der Vaart A; Ziller JW; Furmick JK; Graeber ME; Matro E; Miguel BV; Tran IT; Kwon J; Tedeschi JN; Moosavi S; Danishyar A; Philp JS; Khamees RO; Jackson JN; Grupe DK; Badshah SL; Hart JW
J Med Chem; 2009 Oct; 52(19):5950-66. PubMed ID: 19791803
[TBL] [Abstract][Full Text] [Related]
13. Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
Inoue M; Tanabe H; Nakashima K; Ishida Y; Kotani H
J Nat Prod; 2014 Jul; 77(7):1670-7. PubMed ID: 24959987
[TBL] [Abstract][Full Text] [Related]
14. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
Chou CF; Hsieh YH; Grubbs CJ; Atigadda VR; Mobley JA; Dummer R; Muccio DD; Eto I; Elmets CA; Garvey WT; Chang PL
J Dermatol Sci; 2018 Jun; 90(3):343-356. PubMed ID: 29599065
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status.
Fitzgerald P; Teng M; Chandraratna RA; Heyman RA; Allegretto EA
Cancer Res; 1997 Jul; 57(13):2642-50. PubMed ID: 9205071
[TBL] [Abstract][Full Text] [Related]
16. Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.
Boerma LJ; Xia G; Qui C; Cox BD; Chalmers MJ; Smith CD; Lobo-Ruppert S; Griffin PR; Muccio DD; Renfrow MB
J Biol Chem; 2014 Jan; 289(2):814-26. PubMed ID: 24187139
[TBL] [Abstract][Full Text] [Related]
17. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist).
Takamatsu K; Takano A; Yakushiji N; Morohashi K; Morishita K; Matsuura N; Makishima M; Tai A; Sasaki K; Kakuta H
ChemMedChem; 2008 May; 3(5):780-7. PubMed ID: 18297677
[TBL] [Abstract][Full Text] [Related]
18. Modulation of RXR function through ligand design.
Pérez E; Bourguet W; Gronemeyer H; de Lera AR
Biochim Biophys Acta; 2012 Jan; 1821(1):57-69. PubMed ID: 21515403
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity.
Davies PJ; Berry SA; Shipley GL; Eckel RH; Hennuyer N; Crombie DL; Ogilvie KM; Peinado-Onsurbe J; Fievet C; Leibowitz MD; Heyman RA; Auwerx J
Mol Pharmacol; 2001 Feb; 59(2):170-6. PubMed ID: 11160850
[TBL] [Abstract][Full Text] [Related]
20. Retinoid X receptor agonist elevation of serum triglycerides in rats by potentiation of retinoic acid receptor agonist induction or by action as single agents.
Standeven AM; Thacher SM; Yuan YD; Escobar M; Vuligonda V; Beard RL; Chandraratna RA
Biochem Pharmacol; 2001 Dec; 62(11):1501-9. PubMed ID: 11728386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
